• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Theravance - Articles and news items

revefenacin

Phase 3 programme for revefenacin in COPD starts

Industry news / 14 September 2015 / Victoria White

The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study…

copd

Results from the SUMMIT COPD CV survival study announced

Industry news / 9 September 2015 / Victoria White

For the primary endpoint of the study, the risk of dying on Relvar/Breo Ellipta 100/25mcg was 12.2% lower than on placebo over the study period, which was not statistically significant…

GlaxoSmithKline logo

GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD

Industry news / 16 July 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease…

GlaxoSmithKline logo

Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD

Industry news / 4 July 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases…

GlaxoSmithKline logo

GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma

Industry news / 1 July 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for a fixed dose combination of the inhaled corticosteroid, fluticasone furoate and the long-acting beta2 agonist, vilanterol…

GlaxoSmithKline logo

GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD

Industry news / 11 June 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse™ Ellipta®…

GlaxoSmithKline logo

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS®

Industry news / 14 March 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies…

GlaxoSmithKline logo

Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD

Industry news / 20 February 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol under the proposed brand name Anoro®…

GlaxoSmithKline logo

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

Industry news / 18 November 2013 / GlaxoSmithKline

RELVAR® ELLIPTA® is now licensed across 31 European countries…

GlaxoSmithKline logo

FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD

Industry news, News / 10 September 2013 / GlaxoSmithKline

GSK and Theravance, Inc. announced that the PADAC to the US FDA voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol…

GlaxoSmithKline logo

BREO™ ELLIPTA™ gains US approval for the treatment of COPD

Industry news, News / 10 May 2013 / GlaxoSmithKline

GlaxoSmithKline and Theravance announced that the US FDA has approved BREO™ ELLIPTA™…

GlaxoSmithKline logo

GSK and Theravance announce regulatory submission for ANORO™ ELLIPTA™ in Japan

Industry news, News / 22 April 2013 / GlaxoSmithKline

Submission of a regulatory application to the Japanese MHLW…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +